Keyphrases
Alopecia Areata
100%
United States
28%
Ritlecitinib
28%
Vitiligo
19%
Claims Database
18%
Autoimmune Disease
13%
Incidence Rate
12%
Placebo
12%
Severity of Alopecia Tool
11%
Comorbidity
11%
Hair Loss
9%
Alopecia Totalis
9%
Alopecia Universalis
9%
Prevalence Pattern
9%
Disease Pattern
9%
Mental Health Conditions
9%
Inflammatory Diseases
9%
Randomized Double-blind
9%
Clinical Outcomes
9%
Medical Data Center
9%
Non-interventional
9%
Japanese Patients
9%
Plain Language Summary
9%
Treatment Patterns
9%
Realist Evaluation
9%
Observational Cohort
9%
Administrative Claims Database
9%
Comorbidity Patterns
9%
Japan
9%
Thromboembolism
9%
Cardiovascular Events
9%
Payers
9%
Malignancy
9%
Infection Rate
9%
Infection Events
9%
Managed Care
9%
Brainstem Auditory Evoked Potentials
9%
Intraepidermal Nerve Fiber Density
9%
Histology
9%
Collaborative Efforts
9%
Clinical Application
9%
Systematic Literature Review
9%
Denmark
9%
Patient Perspective
9%
Epidemiology
9%
Functional Impact
9%
Social-emotional
9%
Emotional Impact
9%
Social Impact
9%
Segmental Vitiligo
6%
Medicine and Dentistry
Alopecia Areata
54%
Prevalence
31%
Vitiligo
19%
Alopecia Mucinosa
16%
Comorbidity
14%
Disease
12%
Adolescence
9%
Cohort Effect
9%
Cardiovascular System
9%
Cancer
9%
Thromboembolism
9%
Infection
9%
Systematic Review
9%
Quality of Life
5%
Autoimmune Disease
5%
Pharmacology, Toxicology and Pharmaceutical Science
Alopecia Areata
81%
Placebo
27%
Comorbidity
14%
Prevalence
13%
Hair Loss
10%
Alopecia
10%
Thromboembolism
9%
Infection
9%
Disease
8%
Nerve Fiber Degeneration
6%
Autoimmune Disease
6%
Adverse Event
6%
Minoxidil
5%
